Tag: Parkinson’s
-
New Peer-Reviewed Research Paper: Protecting Overlooked Cells as a New Approach to Parkinson’s
10th of July 2026; Cambridge, UK A translational study published in Experimental Neurology suggests a new experimental therapeutic approach to slowing down Parkinson’s disease progression. The work, led by the University of Cambridge and its spinout Cellestial Health, in collaboration with the University of Manchester among others, shows that communication channels connecting astrocytes – a type of brain cells – break…
-
WPC2026: Three Years Later, Somewhere in Arizona
A very special community came together for the World Parkinson’s Congress on 24-27 May in Phoenix, building on from the strong momentum of the 2023 Congress in Barcelona. The Parkinson’s community showed that it:✦ Sings✦ Dances✦ Paints✦ Researches✦ Never stops What other conference have you been to where the whole audience of a plenary hall drums together at the closing…
-
One Nucleus Awards Gala
Last Thursday 19th of March brought the UK-wide life sciences ecosystem leaders together for a very special occasion of the #ONAwards26 celebration at No.11 Cavendish Square in London. It was a great honour to have the project between Cellestial and The University of Manchester, supported by a Parkinson’s UK grant, recognised as one of the finalist entries in the “Best Industry and…
-
Back at it again in Boston
This week, Dr Nat Hastings represented innovative research into astrocyte pathology in Parkinson’s at the 14th Alzheimer’s & Parkinson’s Drug Development Summit on behalf of Cellestial Health at Hyatt Regency Boston Harbor. Astrocytic lineage is one of the most populous cell types in the brain, yet the damage Parkinson’s pathology does to it remains underappreciated.…
-
BMCS and Parkinson’s UK: New Approaches to the Treatment of Parkinson’s
Dr Nat Hastings represented Cellestial Health at the RSC BMCS and Parkinson’s UK “New Approaches to the Treatment of Parkinson’s” conference on Wednesday 12th, alternating between the corporate exhibitor stand, academic poster presenter, and an audience member of the many insightful talks at the majestic Royal Society of Chemistry halls. Here are the highlights of…
-
CRL Science Day: There is No Such Thing as a Model of Parkinson’s
On Wednesday 24th of September Dr Nat Hastings presented at the Charles River Labs Science Day at Chesterford Research Park on a topic that is relevant to Cellestial’s drug development activities and which stirred many discussions – there is no such things as a model of Parkinson’s disease. What does that mean, when many so-called…
-
Parkinson’s UK: Further Funding for Pioneering Approach
Parkinson’s UK awarded Cellestial Health £55,000 to continue exploring networks of brain cells that may hold answers for new treatments for Parkinson’s. There are many different types of cells in the brain. We know that in Parkinson’s, brain cells that produce dopamine become damaged and start to die over time. However, it’s possible that other…
-
Topic in Spotlight: Brain Delivery
A drug has to be efficacious, safe, and potent – but first of all, it has to get to the right place. On Thursday 10th of July, the Formulation Adviser to Cellestial Health, Prof Claire Thompson of Agility Life Sciences, presented on the topic of formulation choice for proof-of-concept studies in Parkinson’s models at the Bionow…
-
New Paper: Connexin43 is Downregulated in Human Parkinson’s
Translational research often commences in various models – cells, rodents, slice cultures.. But results from all of these rest on an 𝙖𝙨𝙨𝙪𝙢𝙥𝙩𝙞𝙤𝙣 that the underlying cause of the human disease is correctly replicated in the chosen model. There is no single easy way to prove this assumption, especially in a complex and often multi-factorial condition…
-
#21toWatch 2025: Proud to be Short-Listed!
Friends, Cellestial Health is honoured to be shortlisted in the prestigious #21toWatch Companies list – among other impressive contestants such as Lucy Jung, co-founder of Charco Neurotech, and Jonathan Fisher. Both of these inventors are working on wearable devices to reduce motor symptoms of Parkinson’s. At the same time, Arko Paul at Oltera is designing…